Short Interest in Allogene Therapeutics Inc (NASDAQ:ALLO) Increases By 9.6%

Share on StockTwits

Allogene Therapeutics Inc (NASDAQ:ALLO) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 12,830,000 shares, a growth of 9.6% from the December 15th total of 11,710,000 shares. Approximately 26.9% of the shares of the company are sold short. Based on an average trading volume of 537,500 shares, the short-interest ratio is presently 23.9 days.

NASDAQ:ALLO opened at $26.62 on Thursday. The stock has a 50-day simple moving average of $27.34 and a two-hundred day simple moving average of $27.83. Allogene Therapeutics has a 52-week low of $24.60 and a 52-week high of $33.80. The company has a debt-to-equity ratio of 0.06, a current ratio of 15.28 and a quick ratio of 15.28.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.04. As a group, equities analysts predict that Allogene Therapeutics will post -1.93 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in ALLO. Vanguard Group Inc. lifted its position in shares of Allogene Therapeutics by 64.0% in the second quarter. Vanguard Group Inc. now owns 3,443,180 shares of the company’s stock valued at $92,449,000 after acquiring an additional 1,343,459 shares in the last quarter. BlackRock Inc. lifted its position in shares of Allogene Therapeutics by 58.3% in the second quarter. BlackRock Inc. now owns 3,562,333 shares of the company’s stock worth $95,650,000 after buying an additional 1,312,056 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of Allogene Therapeutics in the second quarter worth about $14,967,000. Wildcat Capital Management LLC purchased a new stake in shares of Allogene Therapeutics in the second quarter worth about $14,289,000. Finally, California Public Employees Retirement System lifted its position in shares of Allogene Therapeutics by 409.2% in the third quarter. California Public Employees Retirement System now owns 98,272 shares of the company’s stock worth $2,678,000 after buying an additional 78,972 shares in the last quarter. 55.52% of the stock is owned by institutional investors and hedge funds.

ALLO has been the subject of several research analyst reports. ValuEngine raised Allogene Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, December 30th. JPMorgan Chase & Co. reissued a “hold” rating and set a $29.00 price target on shares of Allogene Therapeutics in a report on Wednesday, November 6th. William Blair reissued a “buy” rating on shares of Allogene Therapeutics in a report on Tuesday, November 5th. Canaccord Genuity initiated coverage on Allogene Therapeutics in a report on Monday, November 4th. They set a “buy” rating and a $36.00 price target for the company. Finally, JMP Securities initiated coverage on Allogene Therapeutics in a report on Wednesday, December 18th. They set an “outperform” rating and a $37.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Allogene Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $36.20.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Featured Article: Google Finance Portfolio

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Allogene Therapeutics Inc  Increases By 9.6%
Short Interest in Allogene Therapeutics Inc Increases By 9.6%
Aerie Pharmaceuticals Inc  Short Interest Update
Aerie Pharmaceuticals Inc Short Interest Update
Short Interest in Adobe Inc  Declines By 10.4%
Short Interest in Adobe Inc Declines By 10.4%
iShares Russell 1000 Value ETF  Hits New 52-Week High at $137.26
iShares Russell 1000 Value ETF Hits New 52-Week High at $137.26
Arbutus Biopharma  Upgraded at Zacks Investment Research
Arbutus Biopharma Upgraded at Zacks Investment Research
Monroe Capital  Given New $11.00 Price Target at B. Riley
Monroe Capital Given New $11.00 Price Target at B. Riley


© 2006-2020 Ticker Report